表紙
市場調査レポート

世界の診断関連提携 :取引動向、企業、金融、予測

Global Diagnostics Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 229679
出版日 ページ情報 英文 3,000+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
世界の診断関連提携 :取引動向、企業、金融、予測 Global Diagnostics Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts
出版日: 2016年04月01日 ページ情報: 英文 3,000+ Pages
概要

当レポートでは、世界の主要企業によって締結された診断関連取引の動向と構造について調査分析し、大手製薬会社の診断関連取引の動向、診断関連取引構造の分析、実際の診断関連取引のケーススタディ、診断関連取引の詳細情報などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 診断関連取引の動向

  • イントロダクション
  • 過去数年の診断関連提携
  • 診断に最も積極的な大手製薬会社
  • 診断に関する提携:契約タイプ別
  • 診断に関する提携:治療分野別
  • 診断に関する提携に対する開示された金融条件
    • 取引総額
    • 前金支払額
    • 目標達成報奨金
    • ロイヤルティ料率

第3章 主要な診断関連取引

  • イントロダクション
  • 診断関連トップ取引:金額別

第4章 診断に最も積極的な取引企業

  • イントロダクション
  • 診断に最も積極的な取引企業
  • 診断に最も積極的な提携企業プロファイル

第5章 診断関連契約取引一覧

  • イントロダクション
  • 診断関連契約取引一覧

第6章 診断関連契約:技術タイプ別

第7章 提携リソースセンター

  • オンライン提携
  • 提携動向
  • 関連資料

付録

  • 付録1:診断関連契約(企業別A-Z)
  • 付録2:診断関連契約(開発ステージ別)
    • 創薬
    • 前臨床
    • フェーズ?
    • フェーズ?
    • フェーズ?
    • 規制
    • 上市
    • 処方
  • 付録3:診断関連契約(タイプ別)
    • 資産購入
    • 譲渡
    • 大手製薬会社のアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同上市
    • 共同プロモーション
    • CRADA
    • クロスライセンシング
    • 開発
    • 流通販売
    • 株式購入
    • 評価
    • 譲与
    • ジョイントベンチャー
    • ライセンシング
    • 訴訟
    • 製造
    • マーケティング
    • 物質移動
    • オプション
    • プロモーション
    • 研究
    • 合意
    • スピンアウト
    • サブライセンス
    • 供給
    • 技術移転
    • 契約解除
    • 保証
  • 付録4:診断関連契約(治療分野別)
  • 付録5:契約タイプの定義

Wildwood Venturesについて

Current Partnering Current Agreements CurrentPartneringの発行タイトル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2104

The ‘Global Diagnostics Partnering 2010-2016’ report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.

  • Comprehensive directory of diagnostic deals since 2010
  • Diagnostic contract documents
  • Diagnostic agreement terms
  • Diagnostic agreement structure
  • Top diagnostic deals by value
  • Most active diagnostic dealmakers

This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:

  • Companion Diagnostics
  • Imaging
  • CT
  • Endoscope
  • Molecular and nuclear
  • MRI
  • Ultrasound
  • X-ray
  • PET
  • SPECT
  • Angiography
  • Fluroscopy
  • Mammography
  • In vitro diagnostics
  • Molecular diagnostics
  • Prognostics
  • Theranostics

The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals.

The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 3,600 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostics technologies and products.

Key benefits

‘Global Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts’ provides the reader with the following key benefits:

  • In-depth understanding of Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Diagnostics dealmakers since 2010
  • Insight into terms included in a Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts’ is intended to provide the reader with an in-depth understanding and access to Diagnostics trends and structure of deals entered into by leading companies worldwide.

Diagnostics Partnering Terms and Agreements includes:

  • Trends in Diagnostics dealmaking in the biopharma industry since 2010
  • Analysis of Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Diagnostics deals
  • Access to Diagnostics contract documents
  • Leading Diagnostics deals by value since 2010
  • Most active Diagnostics dealmakers since 2010

In ‘Global Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts’ report provides comprehensive access to available deals and contract documents for over 3,600 Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. Diagnostics partnering over the years
  • 2.3. Most active Diagnostics dealmakers
  • 2.4. Diagnostics partnering by deal type
  • 2.5. Diagnostics partnering by therapy area
  • 2.6. Deal terms for Diagnostics partnering
    • 2.6.1. Diagnostics partnering headline values
    • 2.6.2. Diagnostics deal upfront payments7
    • 2.6.3. Diagnostics deal milestone payments
    • 2.6.4. Diagnostics royalty rates

Chapter 3 - Leading Diagnostics deals

  • 3.1. Introduction
  • 3.2. Top Diagnostics deals by value

Chapter 4 - Most active Diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active Diagnostics dealmakers
  • 4.3. Most active Diagnostics partnering company profiles

Chapter 5 - Diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Diagnostics contracts dealmaking directory

Chapter 6 - Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Diagnostics deals by company A-Z

Appendix 2 - Diagnostics deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Diagnostics deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Diagnostics deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Diagnostics partnering since 2010
  • Figure 2: Active Diagnostics dealmaking activity- 2010 to 2016
  • Figure 3: Diagnostics partnering by deal type since 2010
  • Figure 4: Diagnostics partnering by disease type since 2010
  • Figure 5: Diagnostics deals with a headline value
  • Figure 6: Diagnostics deals with an upfront value
  • Figure 7: Diagnostics deals with a milestone value
  • Figure 8: Diagnostics deals with a royalty rate value
  • Figure 9: Top Diagnostics deals by value since 2010
  • Figure 10: Most active Diagnostics dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top